Figure 4.
Blockage of DHT production in female recipients transplanted with high AR–expressing AML cells improves the disease outcome. (A) Secondary transplantation was done retro-orbitally with 1° CD45.1 high AR–expressing AML donor cells to CD45.2 WT female recipients; at 1 week after transplantation, the mice were administered 20 mg/kg finasteride daily intraperitoneally for 2 weeks. The mice were euthanized at 3 weeks after transplantation; the blood, bone marrow, and spleen were sampled (n = 5-7 in each group). (B) CBC analysis of recipient mice in panel A at the end point. (C) Spleen weights (milligram) of recipient mice in panel A at the end point. (D-E) Counts of AML cells in the Lin– population in the bone marrow (D) and spleen (E) of recipient mice in panel A at the end point. (F-G) Counts of LICs in the bone marrow (F) and spleen (G) of recipient mice in panel A at the end point. (H) Count of platelets in the periphery of recipient mice in panel A at the end point. (I) Body weight change, expressed as the ratio of body weight before the treatment and at the end point in panel A. (J) Scheme showing female recipients transplanted with high AR–expressing AML donor cells that received the in vivo treatment of intraperitoneal finasteride (20 mg/kg per day) for 2 or 4 weeks. (K) The Kaplan-Meier curve that was used to estimate the survival benefit of in vivo finasteride treatment up to 63 days after transplantation; ∗P < .05; ∗∗P < .01, as determined using a log-rank test. (L) Eight mice in the group of female recipients that were treated with 4 weeks of finasteride (high AR–expressing donor → female + finasteride 4 week) in panel K were euthanized at day 63. The body weights of those mice were measured after transplantation. (M) Spleen weights (mg) of the recipient mice in panel L at the end point. (N) Counts of CD45.1+ AML cells in the bone marrow and spleen of mice in panel L at the end point. Panels B-I, M-N, error bars represent the mean ± SEM of the replicates. ∗P < .05; ∗∗P < .01, as determined using a 1-tailed unpaired Student t test. BA, basophil; Ctl, control; EO, eosinophil; LY, lymphocyte; MO, monocyte; NE, neutrophil; PBS, phosphate-buffered saline.

Blockage of DHT production in female recipients transplanted with high AR–expressing AML cells improves the disease outcome. (A) Secondary transplantation was done retro-orbitally with 1° CD45.1 high AR–expressing AML donor cells to CD45.2 WT female recipients; at 1 week after transplantation, the mice were administered 20 mg/kg finasteride daily intraperitoneally for 2 weeks. The mice were euthanized at 3 weeks after transplantation; the blood, bone marrow, and spleen were sampled (n = 5-7 in each group). (B) CBC analysis of recipient mice in panel A at the end point. (C) Spleen weights (milligram) of recipient mice in panel A at the end point. (D-E) Counts of AML cells in the Lin– population in the bone marrow (D) and spleen (E) of recipient mice in panel A at the end point. (F-G) Counts of LICs in the bone marrow (F) and spleen (G) of recipient mice in panel A at the end point. (H) Count of platelets in the periphery of recipient mice in panel A at the end point. (I) Body weight change, expressed as the ratio of body weight before the treatment and at the end point in panel A. (J) Scheme showing female recipients transplanted with high AR–expressing AML donor cells that received the in vivo treatment of intraperitoneal finasteride (20 mg/kg per day) for 2 or 4 weeks. (K) The Kaplan-Meier curve that was used to estimate the survival benefit of in vivo finasteride treatment up to 63 days after transplantation; ∗P < .05; ∗∗P < .01, as determined using a log-rank test. (L) Eight mice in the group of female recipients that were treated with 4 weeks of finasteride (high AR–expressing donor → female + finasteride 4 week) in panel K were euthanized at day 63. The body weights of those mice were measured after transplantation. (M) Spleen weights (mg) of the recipient mice in panel L at the end point. (N) Counts of CD45.1+ AML cells in the bone marrow and spleen of mice in panel L at the end point. Panels B-I, M-N, error bars represent the mean ± SEM of the replicates. ∗P < .05; ∗∗P < .01, as determined using a 1-tailed unpaired Student t test. BA, basophil; Ctl, control; EO, eosinophil; LY, lymphocyte; MO, monocyte; NE, neutrophil; PBS, phosphate-buffered saline.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal